Dettagli progetto
Description
Hermansky-Pudlak syndrome (HPS) is an inherited multisystem disorder caused by a defect of lysosome-related organelles (LRO) in various tissues, like delta granules in platelets, melanosomes in melanocytes and Weibel Palade Bodies (WPB) in endothelial cells (ECs). HPS is characterized by oculocutaneous albinism with nystagmus and visual acuity loss, bleeding diathesis and, in some cases, extra-hematological complications such as pulmonary fibrosis, granulomatous colitis and immunodeficiency. HPS is caused by genetic variants in 11 different genes, all coding for proteins playing a role in the biogenesis of lysosome-related organelles. The
most severe subtype of HPS is HPS-1, in which variants affect the HPS1 protein that interacts with HPS4 to compose the BLOC-3 complex. Treatment options for inherited platelet disorders (IPD), including HPS, are rather limited, unspecific, and frequently ineffective, therefore further studies are required to define the mechanism of the disease and identify an effective treatment. The mechanisms involved in the pathogenesis of HPS have already been investigated in melanosomes, alveolar epithelial cells and platelet delta granules but little is known about Weibel Palade Bodies (WPB) secretion by ECs. Recently, endothelial colony forming
cells (ECFC) have been isolated from an HPS-2 patient, and in parallel with CRISPR-Cas9-engineered ECs, have been used as a cellular model to study the mechanism of maturation of WPBs and their exocytosis in HSP-2 suggesting a link between impaired endothelial cell function and bleedings. However, little is known about the maturation and storage of WPBs in HPS-1. Moreover, induced pluripotent stem cells (iPSCs) have been generated from the reprogramming of somatic cells of HSP-1 patients, but they were not differentiated in any relevant cell to be used in HSP. Therefore, this project aims to shed new light on the pathogenesis of
HPS-1 and to develop for the first time a cell and gene approach to correct genetic variants causing HPS-1. Hence, we first aim to investigate the endothelial function and WPB secretion of ECFCs isolated from an HPS-1 patient. Secondly, we will generate iPSCs from an HPS-1 patient, and differentiate them into megakaryocytes and subsequently obtain platelets, to study dense granule content and release. Finally, we will develop a cell and gene therapy strategy, based on the use of lentiviral vectors carrying the HSP1 gene under the control of an endothelial or a megakaryocyte promoter, to correct the genetic defect in HPS-1 ECFCs and
iPSCs-derived megakaryocytes. The findings deriving from this project will expand knowledge on a very rare inherited disorder, moreover, the concept that the
bleeding phenotype of patients with HPS may be due not only to the well-known platelet defect but also to a defect in endothelial cells is very pioneering and may change the therapeutic approach to this disorder.
Stato | Attivo |
---|---|
Data di inizio/fine effettiva | 30/11/23 → 29/11/25 |
Funding
- MUR - Ministero dell'Università e Ricerca
Obiettivi di sviluppo sostenibile dell’ONU
Nel 2015, gli Stati membri dell'ONU hanno sottoscritto 17 obiettivi globali di sviluppo sostenibile (OSS) per porre fine alla povertà, salvaguardare il pianeta e assicurare prosperità a tutti. Il presente lavoro contribuisce al raggiungimento dei seguenti OSS:
Keywords
- induced pluripotent stem cells (iPSCs)
- endothelial colony forming cells
- lentiviral vector
- cell and gene therapy
- Hermansky-Pudlak syndrome
- megakaryocytes
Fingerprint
Esplora i temi di ricerca toccati da questo progetto. Queste etichette sono generate sulla base dei riconoscimenti/sovvenzioni sottostanti. Insieme formano una fingerprint unica.